Chaperon Enhances Drug Development Platform by Recruiting AI Experts... "Dramatic Reduction in Time and Cost"

Chaperon announced on the 12th that it has recruited an expert to design and implement prediction models such as the ‘Drug-Target Interaction (DTI)’ prediction model and the ‘MHC-Peptide Binding’ prediction model to advance its proprietary AI drug development platform, ‘AIDEN’.

The AI expert recruited by Chaperon possesses extensive experience in the bio AI field, including data preprocessing and visualization for DTI prediction models and MHC-peptide binding prediction models, AI model design and implementation, and AI data training.

Through this expert recruitment, Chaperon expects to drastically shorten the development time and costs not only for next-generation synthetic drugs but also for ‘Nano Mab’ development. Additionally, by improving the performance of algorithms such as drug response prediction models and toxicity prediction models, the company plans to further enhance prediction accuracy.

Chaperon aims to shorten the lead compound discovery for new pipelines to within six months and increase drug response prediction rates to over 95% through the advancement of its AI platform. This will accelerate not only new drug development but also the development of Nanomap antibody therapeutics.

The Nanomap drug development technology previously required a significant amount of time to find antibodies that precisely match the desired targets. However, through the advancement of AI technology, this period can be significantly reduced. Utilizing the new AI platform allows for reducing the time needed to optimize the core regions of Nanomap and improving accuracy. Tasks that previously took several months are now shortened to within three months, enabling faster delivery of therapeutics to patients.

Insilico Medicine, headquartered in the United States and Hong Kong, has a case of successfully designing and synthesizing drug candidates in just 46 days using AI. In 2020, it also achieved the milestone of entering clinical trials with an AI-developed drug candidate for the first time. Insilico Medicine specializes in developing drug candidates related to chronic pulmonary diseases and oncology using AI and machine learning.

Using AIDEN, Chaperon achieved the result of securing dozens of compounds in the first half of this year that exhibit more than 100 times superior inflammasome inhibition function in vitro compared to existing drugs. AIDEN is a drug development platform based on inflammasome-related data accumulated over the past 15 years and global inflammation-related data.

A Chaperon official stated, “We will continuously advance AI technology to more precisely predict the safety and efficacy of synthetic drugs based on the AIDEN platform. Through this, we will accelerate the development of proprietary Nanomap technology that surpasses the ‘Nanobody’ technology of competitor Sanofi and leap forward as a global top-tier inflammasome-targeting drug development company.”

He added, “To predict target-antibody interactions, binding affinity, and precise antigen recognition sites necessary for Nanomap development, we will enhance the AI platform and develop Nanomap antibody therapeutics for various indications to generate outcomes such as early technology transfers. Furthermore, Nanomap drug development technology can be applied to viral diseases like mpox, which is currently spreading mainly in Africa, enabling rapid response to emerging infectious diseases.”

This content was produced with the assistance of AI translation services.